BioCentury

@BioCentury

The leading voice for decision makers throughout the global healthcare ecosystem.

Vrijeme pridruživanja: prosinac 2010.

Tweetovi

Blokirali ste korisnika/cu @BioCentury

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @BioCentury

  1. prije 11 sati

    Gilead's O'Day on remdesivir: 'We will not get in a patent dispute'

    Poništi
  2. prije 12 sati

    Wednesday's management moves roundup include BioMarin's CFO stepping down, new execs for Atara and Epirium, and more

    Poništi
  3. prije 12 sati

    Initial efficacy data suggest CAR NK cells could compete with CAR Ts in blood cancers.

    Poništi
  4. prije 13 sati

    After Merck spins out slower-growing businesses to focus on innovation, the company will need recent and future deals to yield fruit in order to balance its reliance on Keytruda for growth

    Poništi
  5. prije 14 sati

    Trump endorses Grassley-Wyden drug pricing bill

    Poništi
  6. prije 15 sati

    A big win for on IPR, adding nearly $9B in market cap. With overhang lifted, investors now turn full attention to candidate

    Poništi
  7. prije 15 sati

    FDA's Richard Pazdur supports expanded access for unapproved uses of approved drugs

    Poništi
  8. prije 15 sati

    EMA hopes to lower barriers to use of real-world data in regulatory decision making by creating a centralized system for integrating RWD across Europe.

    Poništi
  9. proslijedio/la je Tweet
    5. velj

    .'s Vijay Pande tells 's the firm is investing new $750M fund in “weak AI” -- speeding and scaling up tasks humans can do -- while tech that could enable “strong AI,” which does things humans can’t do, matures.

    Poništi
  10. proslijedio/la je Tweet
    prije 21 sat

    3/ Clinical trial delays in China could have a wide impact on the global biopharma industry. More analysis here from my colleague ->

    Prikaži ovu nit
    Poništi
  11. proslijedio/la je Tweet
    5. velj

    2/ICYMI: Draft report from R&D Blueprint Clinical Trials expert group singles out Gilead's remdesivir as most promising candidate for (free analysis) via

    Prikaži ovu nit
    Poništi
  12. proslijedio/la je Tweet
    4. velj

    We have created a free webpage that collects analysis of the outbreak. Please bookmark this page. It will be updated frequently. The most recent story tracks clinical trials.

    Prikaži ovu nit
    Poništi
  13. 5. velj

    Andreessen Horowitz GPs see opportunities for "weak AI," diagnostics and synthetic biology with $750M Bio Fund III

    Poništi
  14. proslijedio/la je Tweet
    Poništi
  15. proslijedio/la je Tweet
    4. velj
    Poništi
  16. proslijedio/la je Tweet
    4. velj

    Delays hit clinical trials in China. 's speaks with Foundation's Dan Zhang and HitGen's Jin Li on 's impact on clinical research. For open access to all of BioCentury's coverage see:

    Poništi
  17. proslijedio/la je Tweet
    4. velj

    to begin enrolling patients mid-Feb in 2 trials of to treat acute respiratory disease via 's

    Poništi
  18. proslijedio/la je Tweet
    5. velj

    . draft report: 's remdesivir most "promising" candidate to treat , planning for trial under way. says its “investing pretty heavily” in manufacturing of the therapy “to make sure we’re prepared as best as we can” via

    Poništi
  19. proslijedio/la je Tweet
    5. velj

    CEO O'Day: has sense of "urgency" for M&A, seeking “transformative" deals a la , as well as small- to medium-sized bolt-on takeouts. Co also working “night and day” to ramp up manufacturing for therapy via 's

    Poništi
  20. proslijedio/la je Tweet
    5. velj

    At least 22 MNCs are sponsoring interventional trials in China, 18 have trial sites in Wuhan, the epicenter of the outbreak. An analysis of cos most active in the region finds Roche could be most affected. via

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·